BMC Cancer最新文献

筛选
英文 中文
Efficacy and safety of combining tislelizumab with capecitabine compared to capecitabine alone in the adjuvant treatment of biliary tract cancers: rationale and protocol design for a randomized clinical trial. 与单独卡培他滨相比,tislelizumab联合卡培他滨辅助治疗胆道癌症的疗效和安全性:一项随机临床试验的基本原理和方案设计
IF 3.4 2区 医学
BMC Cancer Pub Date : 2025-05-25 DOI: 10.1186/s12885-025-14367-7
Xubiao Wei, Yabo Jiang, Jinxue Zhou, Hongkun Zhou, Dong Qu, Xiaofei Ye, Yaxin Zheng, Shuqun Cheng
{"title":"Efficacy and safety of combining tislelizumab with capecitabine compared to capecitabine alone in the adjuvant treatment of biliary tract cancers: rationale and protocol design for a randomized clinical trial.","authors":"Xubiao Wei, Yabo Jiang, Jinxue Zhou, Hongkun Zhou, Dong Qu, Xiaofei Ye, Yaxin Zheng, Shuqun Cheng","doi":"10.1186/s12885-025-14367-7","DOIUrl":"10.1186/s12885-025-14367-7","url":null,"abstract":"<p><strong>Background: </strong>Adjuvant therapy with capecitabine is recommended to improve survival for resectable biliary tract cancers (BTC) patients. Considering that the combination of PD-1/PD-L1 inhibitors with chemotherapy has demonstrated a survival benefit over chemotherapy alone in advanced stage BTC, we aim to evaluate the treatment efficacy and safety of tislelizumab, a PD-1 inhibitor, combined with capecitabine vs. capecitabine alone as an adjuvant treatment in patients with resectable BTC.</p><p><strong>Method: </strong>This multicenter randomized controlled study will include a total of 140 patients who will have undergone curative resection within 4 weeks prior to enrollment and will have been pathologically diagnosed with cholangiocarcinoma (including intrahepatic and extrahepatic cholangiocarcinoma) or muscle-invasive gallbladder carcinoma. Those patients will be randomly assigned 1:1 to tislelizumab combined with capecitabine or capecitabine alone group. The primary endpoint will be recurrence free survival (RFS), the secondary endpoints will be overall survival (OS) and adverse events (AEs). Multi-omics biomarkers will be assessed as exploratory objective.</p><p><strong>Discussion: </strong>There remains a major unmet need for more effective adjuvant therapies for resectable BTC. If this study demonstrates that adding tislelizumab enhances the therapeutic efficacy of capecitabine, this combined regimen will potentially improve the prognosis of patients with resectable BTC. In addition, we will analyze the relationship between various gene expression profiles and clinical endpoint events to define the ideal patient population receiving adjuvant immunotherapy.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"938"},"PeriodicalIF":3.4,"publicationDate":"2025-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12103743/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144141439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
MicroRNAs involved in colorectal cancer, a rapid mini-systematic review. 参与结直肠癌的microrna,一个快速的小系统回顾。
IF 3.4 2区 医学
BMC Cancer Pub Date : 2025-05-24 DOI: 10.1186/s12885-025-14343-1
Sogol Shirzad, Majid Eterafi, Zeinab Karimi, Mahdi Barazesh
{"title":"MicroRNAs involved in colorectal cancer, a rapid mini-systematic review.","authors":"Sogol Shirzad, Majid Eterafi, Zeinab Karimi, Mahdi Barazesh","doi":"10.1186/s12885-025-14343-1","DOIUrl":"10.1186/s12885-025-14343-1","url":null,"abstract":"<p><strong>Introduction: </strong>Colorectal cancer (CRC) involves the uncontrolled proliferation of glandular epithelial cells in the colon or rectum. The high mortality rate associated with CRC has driven extensive research into innovative diagnostic and therapeutic strategies. Among these, microRNAs (miRNA) have gained attention for their crucial role in regulating various cellular processes that contribute to the initiation, progression, and metastasis of CRC.</p><p><strong>Method: </strong>This systematic review aimed to assess the roles of various miRNAs in CRC by analyzing multiple studies. The PICO framework was followed to structure the study regarding miRNA involved in CRC development and progression compared to normal cases. The outcomes were measured according miRNAs impact on CRC progression, survival rates, and treatment response. Systematic review of studies published from 2000 to November 2023 were included. Data were collected from prominent databases, including Google Scholar, PubMed, ScienceDirect, Irandoc, SID, and Magiran, covering studies from 2000 to November 2023. Studies were managed using EndNote for citation management, and duplicates were removed. The remaining studies were evaluated based on predefined inclusion and exclusion criteria.</p><p><strong>Results: </strong>In our review, we categorized 28 miRNAs based on their potential tumor suppressor or oncogenic effects in CRC progression. Among them, 14 miRNAs were highlighted as important based on the assessment using TCGA data, with miR-200a also showing a significant effect on patient survival.</p><p><strong>Conclusion: </strong>This study compiled and analyzed validated miRNAs associated with CRC progression. The findings suggest the potential of these miRNAs as non-invasive biomarkers, which may be used alone or in combination with traditional tumor markers for improved diagnostic and prognostic applications in CRC. This review contributes novel insights by updating the current understanding and offering a comprehensive evaluation of miRNAs in CRC.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"934"},"PeriodicalIF":3.4,"publicationDate":"2025-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12103762/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144141440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical benefit of continuation of PD-1 inhibitors after progression on first-line chemoimmunotherapy in metastatic gastric cancer and biomarker exploration. 转移性胃癌一线化疗免疫治疗进展后继续使用PD-1抑制剂的临床获益及生物标志物探索
IF 3.4 2区 医学
BMC Cancer Pub Date : 2025-05-24 DOI: 10.1186/s12885-025-14286-7
Mengwei Zhang, Long Bai, Jianwen Chen, Qi Meng, Yunxin Lu, Dongsheng Zhang
{"title":"Clinical benefit of continuation of PD-1 inhibitors after progression on first-line chemoimmunotherapy in metastatic gastric cancer and biomarker exploration.","authors":"Mengwei Zhang, Long Bai, Jianwen Chen, Qi Meng, Yunxin Lu, Dongsheng Zhang","doi":"10.1186/s12885-025-14286-7","DOIUrl":"10.1186/s12885-025-14286-7","url":null,"abstract":"<p><strong>Background: </strong>Whether continuing immunotherapy after progression in second-line settings of metastatic gastric cancer (MGC) remains unclear. Herein, we explored the efficacy of PD-1 inhibitors for MGC after progression on previous chemoimmunotherapy.</p><p><strong>Methods: </strong>We retrospectively identified MGC patients who received oxaliplatin-based chemotherapy plus PD-1 inhibitor, with or without trastuzumab, as first-line treatment. The patients received treatment with or without PD-1 inhibitors beyond progression in patients with MGC were divided into treatment beyond progression (TBP) group and non-TBP (NTBP) group. The median progression free survival (PFS) and overall survival (OS) from the start of treatment after progression were assessed.</p><p><strong>Results: </strong>The mOS and mPFS in the TBP group was significantly longer than that in the NTBP group (mOS: 9.0 vs. 5.0 months, P = 0.011; mPFS: 4.3 vs. 2.7 months, P = 0.03). Moreover, TBP was an independent prognostic factor for both PFS and OS in multivariate analysis. In the subgroup analysis, patients who were male, had a favorable ECOG (0-1), classified into diffuse histologic subtype and achieved disease control in the prior chemoimmunotherapy, might be more likely to benefit from continuing immunotherapy compared to discontinuation beyond progression.</p><p><strong>Conclusion: </strong>PD-1 inhibitors based therapeutic strategy may be a reasonable option in second-line setting for MGC who progressed on prior immunotherapy. Further larger prospective trials are warranted to validate these findings.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"935"},"PeriodicalIF":3.4,"publicationDate":"2025-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12103759/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144141262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical prediction of pathological complete response in breast cancer: a machine learning study. 乳腺癌病理完全缓解的临床预测:机器学习研究。
IF 3.4 2区 医学
BMC Cancer Pub Date : 2025-05-23 DOI: 10.1186/s12885-025-14335-1
Chongwu He, Tenghua Yu, Liu Yang, Longbo He, Jin Zhu, Jing Chen
{"title":"Clinical prediction of pathological complete response in breast cancer: a machine learning study.","authors":"Chongwu He, Tenghua Yu, Liu Yang, Longbo He, Jin Zhu, Jing Chen","doi":"10.1186/s12885-025-14335-1","DOIUrl":"10.1186/s12885-025-14335-1","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to develop and validate machine learning models to predict pathological complete response (pCR) after neoadjuvant therapy in patients with breast cancer patients.</p><p><strong>Methods: </strong>Clinical and pathological data from 1143 patients were analyzed, encompassing variables such as age, gender, marital status, histologic grade, T stage, N stage, months from diagnosis to treatment, molecular subtype, and response to neoadjuvant therapy. Seven machine learning models were trained and validated using both internal and external datasets. Model performance was evaluated using multiple metrics, and interpretability analysis was conducted to assess feature importance.</p><p><strong>Results: </strong>Key variables influencing pCR included grade, N stage, months from diagnosis to treatment, and molecular subtype. The Naive Bayes model emerged as the most effective, with accuracy (0.746), sensitivity (0.699), specificity (0.808), and F1 score (0.759) surpassing other models. Both internal and external validation confirmed the model's robust predictive power. A web tool was developed for clinical use, aiding in personalized treatment planning. Interpretability analysis further elucidated the contribution of features to pCR prediction, enhancing clinical applicability.</p><p><strong>Conclusion: </strong>The Naive Bayes model provides a robust tool for personalized treatment decisions in patients with breast cancer undergoing neoadjuvant therapy. By accurately predicting pCR rates, it enables clinicians to tailor treatment strategies, potentially improving outcomes.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"933"},"PeriodicalIF":3.4,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12102924/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144131805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction: Hospital factors and metastatic surgery in colorectal cancer patients, a population-based cohort study. 更正:医院因素和结直肠癌患者转移性手术,一项基于人群的队列研究。
IF 3.4 2区 医学
BMC Cancer Pub Date : 2025-05-23 DOI: 10.1186/s12885-025-14339-x
Malin Ljunggren, Caroline E Dietrich, Emma Rosander, Gabriella Palmer, Bengt Glimelius, Anna Martling, Caroline Nordenvall
{"title":"Correction: Hospital factors and metastatic surgery in colorectal cancer patients, a population-based cohort study.","authors":"Malin Ljunggren, Caroline E Dietrich, Emma Rosander, Gabriella Palmer, Bengt Glimelius, Anna Martling, Caroline Nordenvall","doi":"10.1186/s12885-025-14339-x","DOIUrl":"10.1186/s12885-025-14339-x","url":null,"abstract":"","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"929"},"PeriodicalIF":3.4,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12100949/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144131810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Causal role of immune cells in primary liver cancer: a mendelian randomization study. 免疫细胞在原发性肝癌中的因果作用:孟德尔随机研究。
IF 3.4 2区 医学
BMC Cancer Pub Date : 2025-05-23 DOI: 10.1186/s12885-025-14327-1
Jia Liu, Tongyuan Zhang, Yang Gao, Dong Ji, Lijian Chen
{"title":"Causal role of immune cells in primary liver cancer: a mendelian randomization study.","authors":"Jia Liu, Tongyuan Zhang, Yang Gao, Dong Ji, Lijian Chen","doi":"10.1186/s12885-025-14327-1","DOIUrl":"10.1186/s12885-025-14327-1","url":null,"abstract":"<p><strong>Background: </strong>Primary liver cancer is one of the most common fatal malignancies worldwide. Observational studies have shown that immune cells are closely linked to primary liver cancer, however, due to issues like reverse causality and confounding variables, the causal direction and extent of this association remain unclear. Thus, this study aimed to explore the potential causal association between immune cells and primary liver cancer, encompassing hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC).</p><p><strong>Methods: </strong>A two-sample mendelian randomization (MR) analysis was performed using summary statistics from genome-wide association studies (GWAS) of the 731 immune traits and primary liver cancer. The primary liver cancer dataset consisted of a total of 456,348 subjects, with 123 cases of HCC and 456,225 controls, as well as 104 cases of ICC and 456,244 controls, all of European ancestry. The primary method for assessing causality was inverse variance weighting (IVW), with sensitivity analysis utilized for testing heterogeneity and pleiotropy.</p><p><strong>Results: </strong>Two immunophenotypes were significantly associated with HCC risk: CD3 on CD45RA + CD4+ (OR [95% CI]: 1.334 [1.077 to 1.651], p = 0.008), CD80 on monocyte (OR [95% CI]: 0.578 [0.397 to 0.844], p = 0.004). Additionally, six immunophenotypes were identified to be significantly associated with the risk of ICC: SSC-A on NK (OR [95% CI]: 1.685 [1.166 to 2.436], p = 0.006); CD3 on CD28- CD8br: (OR [95% CI]: 1.826 [1.206 to 2.766], p = 0.004); CD45RA on naive CD4+: (OR [95% CI]: 1.391 [1.119 to 1.729], p = 0.003); Resting Treg %CD4: (OR [95% CI]: 1.290 [1.069 to 1.558], p = 0.008); HLA DR on HSC: (OR [95% CI]: 0.539 [0.343 to 0.846], p = 0.007); Plasmacytoid DC %DC: (OR [95% CI]: 0.610 [0.462 to 0.806], p < 0.001). And sensitivity analyses confirmed the robustness of the main findings.</p><p><strong>Conclusions: </strong>MR analysis has revealed the causal relationship between immune cells and primary liver cancer through genetic methods. These findings could assist in clinical decision-making and provide new directions for the treatment and research of primary liver cancer.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"928"},"PeriodicalIF":3.4,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12100895/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144131783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prognostic significance of the number of hepatic lesions in multifocal intrahepatic cholangiocarcinoma after radical resection: an IPTW propensity-score analysis. 多灶性肝内胆管癌根治性切除后肝脏病变数量的预后意义:IPTW倾向评分分析。
IF 3.4 2区 医学
BMC Cancer Pub Date : 2025-05-23 DOI: 10.1186/s12885-025-13737-5
Xin Zhang, Xi-Tai Huang, Jin-Zhao Xie, Ai-Qing Fu, Wei Chen, Jian-Peng Cai, Li-Jian Liang, Xiao-Yu Yin
{"title":"Prognostic significance of the number of hepatic lesions in multifocal intrahepatic cholangiocarcinoma after radical resection: an IPTW propensity-score analysis.","authors":"Xin Zhang, Xi-Tai Huang, Jin-Zhao Xie, Ai-Qing Fu, Wei Chen, Jian-Peng Cai, Li-Jian Liang, Xiao-Yu Yin","doi":"10.1186/s12885-025-13737-5","DOIUrl":"10.1186/s12885-025-13737-5","url":null,"abstract":"<p><strong>Background: </strong>Multifocal hepatic lesions represent a distinctive subgroup within intrahepatic cholangiocarcinoma(iCCA), the management of these patients remains controversial. This study aimed to compare the survival of intrahepatic cholangiocarcinoma (iCCA) with different numbers of hepatic lesions and select patients benefiting most from surgery in multifocal iCCA.</p><p><strong>Methods: </strong>A cohort of 354 consecutive iCCA patients were included. Based on the number of hepatic lesions, patients were classified as follows: solitary tumors (type I), 2 or 3 hepatic lesions in the same-sided hepatic lobe (type II), and more than three hepatic lesions in the same-sided hepatic lobe (type III). Stabilized inverse probability treatment weighting (IPTW) was conducted for accurate prognosis comparisons. Furthermore, the long-term prognosis was compared between different American Joint Committee on Cancer.</p><p><strong>Results: </strong>Among all patients, multifocal iCCA presented significantly worse overall survival (OS) and recurrence-free survival (RFS) than solitary tumor (p < 0.001 and p < 0.001), 11.9% (n = 42), and 14.4% (n = 51) patients were classified into type II, and type III, respectively. After IPTW, type II exhibited similar while type III exhibited worse RFS and OS to type I cohort (solitary tumors) (p < 0.001and p < 0.001). Multivariable Cox analysis also identified type III tumors as an independent risk factor for OS (HR 1.95, 95% CI:1.33-2.87, p < 0.001). Among AJCC stage II (T2N0M0) patients, multifocal iCCA presented significantly worse OS than solitary tumors (vascular invasion) (p = 0.018), and type II exhibited similar while type III exhibited worse OS than solitary tumors (p = 0.500 and p = 0.040). Compared with stage III patients, type II exhibited better while type III exhibited similar OS (p < 0.001 and p = 0.300).</p><p><strong>Conclusions: </strong>Multifocal iCCA presented a significantly worse prognosis, the number of hepatic lesions significantly influenced the prognosis of multifocal iCCA. Patients with type II tumors may derive comparable oncological benefits from surgery compared with solitary tumors, radical surgery still be strongly recommended as the preferred treatment.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"930"},"PeriodicalIF":3.4,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12101014/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144131828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
High-dose third-generation EGFR-TKIs combined with intrathecal pemetrexed in advanced EGFR-mutant NSCLC with leptomeningeal metastases following EGFR-TKI therapy. 高剂量第三代EGFR-TKI联合鞘内培美曲塞治疗EGFR-TKI治疗后发生轻脑膜转移的晚期egfr突变NSCLC。
IF 3.4 2区 医学
BMC Cancer Pub Date : 2025-05-23 DOI: 10.1186/s12885-025-14337-z
Shugui Wu, Zhengang Qiu, Huaqiu Shi, Wei Yu, Linfang Liu, Longqiu Wu, Wenjuan Zhong
{"title":"High-dose third-generation EGFR-TKIs combined with intrathecal pemetrexed in advanced EGFR-mutant NSCLC with leptomeningeal metastases following EGFR-TKI therapy.","authors":"Shugui Wu, Zhengang Qiu, Huaqiu Shi, Wei Yu, Linfang Liu, Longqiu Wu, Wenjuan Zhong","doi":"10.1186/s12885-025-14337-z","DOIUrl":"10.1186/s12885-025-14337-z","url":null,"abstract":"<p><strong>Background: </strong>Leptomeningeal metastasis in EGFR-mutant (EGFRm) non-small-cell lung cancer (NSCLC) is a severe complication particularly prevalent in patients who have previously been treated with EGFR-tyrosine kinase inhibitors (EGFR-TKIs). However, an optimal treatment strategy for dealing with leptomeningeal metastases in patients with NSCLC has yet to be developed. High-dose EGFR-TKIs in combination with intrathecal chemotherapy may offer a promising treatment strategy for this patient population.</p><p><strong>Methods: </strong>We retrospectively identified patients with EGFRm NSCLC who were diagnosed at the First Affiliated Hospital of Gannan Medical University between January 1, 2018, and December 31, 2023. All patients developed leptomeningeal metastases after EGFR-TKI treatment and then received intrathecal pemetrexed chemotherapy in combination with high-dose third-generation EGFR-TKIs (osimertinib 160 mg/day, furmonertinib 160 mg/day, or aumolertinib 165 mg/day), with or without other therapies. Intracranial response, intracranial progression-free survival, overall survival, and safety were evaluated.</p><p><strong>Results: </strong>Twenty-three patients were enrolled. The median follow-up was 20 months (range, 2-35). The median number of intrathecal pemetrexed injections was 4 (range, 2-26). The intracranial symptom relief rate was 91.3% (21/23), intracranial disease control rate was 86.96% (20/23), median intracranial progression-free survival was 10 months (95% CI, 1.52-18.48), and median overall survival was 12 months (95% CI, 5.43-18.57). The most frequent adverse event was myelosuppression (n = 10, 43.48%), which was limited to grade 1 or 2. Two grade 3 adverse events were observed, including one case of interstitial pneumonia and one case of diarrhea. Univariate and multivariate analyses demonstrated that the combination of bevacizumab and an Eastern Cooperative Oncology Group performance status of ≤ 1 were favorable prognostic factors for survival.</p><p><strong>Conclusions: </strong>High-dose third-generation EGFR-TKIs combined with pemetrexed intrathecal chemotherapy demonstrated a high rate of intracranial symptom relief and manageable safety in patients with EGFRm NSCLC who developed leptomeningeal metastases after previous EGFR-TKI therapy.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"926"},"PeriodicalIF":3.4,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12101007/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144131824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tumor suppressing function of SLC16A7 in bladder cancer and its pan-cancer analysis. SLC16A7在膀胱癌中的抑瘤功能及其泛癌分析。
IF 3.4 2区 医学
BMC Cancer Pub Date : 2025-05-23 DOI: 10.1186/s12885-025-14345-z
Mingjie Xu, Jiatong Zhou, Jiancheng Lv, Yu Zhang
{"title":"Tumor suppressing function of SLC16A7 in bladder cancer and its pan-cancer analysis.","authors":"Mingjie Xu, Jiatong Zhou, Jiancheng Lv, Yu Zhang","doi":"10.1186/s12885-025-14345-z","DOIUrl":"10.1186/s12885-025-14345-z","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Bladder cancer (BCa), a prevalent malignancy of the urinary tract, is associated with high recurrence and mortality rates. SLC16A7, a member of the solute carrier family 16 (SLC16), encodes monocarboxylate transporters that are involved in the proton-coupled transport of metabolites, including lactate, pyruvate, and ketone bodies, across cell membranes. Evidence suggests that SLC16A7 exhibits variable expression in cancers and may influence tumor development, progression, and immune regulation. This study examined the role of SLC16A7 in cancer prognosis, progression, and immune regulation, focusing on BCa.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;A comprehensive analysis was conducted to evaluate the clinical and immunological relevance of SLC16A7 across multiple cancer types using data from 33 tumor datasets from 'The Cancer Genome Atlas (TCGA). ' Associations between SLC16A7 expression and clinicopathological features, prognostic indicators, tumor mutation burden (TMB), microsatellite instability (MSI), immune cell infiltration, and immune-related gene expression were systematically analyzed. Experimental validation was performed to assess SLC16A7 expression in the BCa tissues and cell lines. The prognostic value of SLC16A7 was confirmed using clinical follow-up data from an independent patient cohort. Functional studies included proliferation assays to investigate the effect of SLC16A7. CD8 + T cells were obtained from the peripheral blood of healthy donors and stimulated using CD3 and CD28 antibodies in combination with recombinant IL-2. To investigate the immunological role of SLC16A7, co-culture experiments were performed between BCa cells and activated CD8 + T cells. Additionally, CD8 + T cell chemotaxis assays and ELISA analyses were conducted to evaluate the immune responses mediated by SLC16A7.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;SLC16A7 expression was downregulated in 16 cancer types, including BCa, and upregulated in three cancer types. Its expression was significantly associated with tumor stage in four cancers and showed both positive and negative correlations with prognosis, depending on the cancer type. Genomic analyses revealed significant associations between SLC16A7 and TMB in 13 cancer types and MSI in 11 cancer types. Pathway enrichment analyses (Hallmark-GSEA and KEGG-GSEA) indicated strong associations between SLC16A7, immune responses, and tumor progression. Immune infiltration analysis showed a predominantly positive association between SLC16A7 expression and immune cell infiltration, except in low-grade gliomas (LGG). CIBERSORT analysis demonstrated that SLC16A7 expression correlated positively with resting memory CD4 T cells, eosinophils, monocytes, resting mast cells, and memory B cells and negatively with activated memory CD4 T cells, M1 macrophages, follicular helper T cells, M0 macrophages, and CD8 T cells. SLC16A7 expression was also significantly associated with the expression of immune-regulato","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"932"},"PeriodicalIF":3.4,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12102997/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144131846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effects of individualized PEEP on pulmonary function, cerebral blood flow and postoperative cognitive function in patients undergoing laparoscopic radical resection of rectal cancer. 个体化PEEP对腹腔镜直肠癌根治术患者肺功能、脑血流及术后认知功能的影响
IF 3.4 2区 医学
BMC Cancer Pub Date : 2025-05-23 DOI: 10.1186/s12885-025-14321-7
Xiaoyan Zhang, Jingjing Zhang, Caixia Zhao, Yichao Cai, Qing Yang, Caixia Yue, Kan Li
{"title":"Effects of individualized PEEP on pulmonary function, cerebral blood flow and postoperative cognitive function in patients undergoing laparoscopic radical resection of rectal cancer.","authors":"Xiaoyan Zhang, Jingjing Zhang, Caixia Zhao, Yichao Cai, Qing Yang, Caixia Yue, Kan Li","doi":"10.1186/s12885-025-14321-7","DOIUrl":"10.1186/s12885-025-14321-7","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the effects of individualized PEEP on pulmonary function, cerebral blood flow, and postoperative cognitive function in patients undergoing laparoscopic radical resection of rectal cancer.</p><p><strong>Methods: </strong>100 patients who underwent laparoscopic radical rectal cancer surgery at our hospital between August 2021 and May 2023 were randomized into two groups: the DP group (optimal PEEP group oriented to driving pressure) and the Cdyn group (optimal PEEP group oriented to pulmonary compliance). Anesthesia was induced in both groups with 0.3 mg/kg of remizolam + 0.15 mg/kg of CIS atracurium + 0.5 ug/kg of sufentanil. Lung ultrasound score (LUS), peak and plateau airway pressures (PEAK, PLAT), oxygenation index (OI), driving pressure (DP), and pulmonary dynamic compliance (Cdyn) were measured at different time points. Cerebral blood flow and cognitive function were also assessed. T<sub>0</sub>: before induction of anesthesia; T<sub>1</sub>: before postoperative extubation of the tracheal tube; T<sub>2</sub>: 1 h after extubation; T<sub>3</sub>: on the third postoperative day; T<sub>4</sub>: 5 min after determining the optimal PEEP; T<sub>5</sub>: 1 h after the establishment of pneumoperitoneum; T<sub>6</sub>: 2 h after the establishment of the pneumoperitoneum; T<sub>7</sub>: 20 min at the end of pneumoperitoneum.</p><p><strong>Results: </strong>There were no significant differences in general information between the two groups, P > 0.05. Compared with the DP group, the Cdyn group had lower LUS at T<sub>3</sub>, higher PEAK at T<sub>5</sub>, T<sub>6</sub>, and T<sub>7</sub>, lower PLAT and OI at T<sub>6</sub> and T<sub>7</sub>, lower DP at T<sub>4</sub>, T<sub>6</sub>, and T<sub>7</sub>, and lower Cdyn at T<sub>6</sub> and T<sub>7</sub>, P < 0.05. The Cdyn group had lower cerebral blood flow at T<sub>4</sub> and T<sub>6</sub>, P < 0.05. The Cdyn group had higher cognitive function at stage T<sub>3</sub> as assessed by MMSE, P < 0.05.</p><p><strong>Conclusion: </strong>PEEP guided by lung compliance improves pulmonary function, cerebral blood flow, and cognitive function, offering clinical benefits.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"927"},"PeriodicalIF":3.4,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12100997/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144131829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信